Literature DB >> 8396402

Antibodies in human sera recognizing a recombinant outer membrane protein encoded by the envelope gene of the human endogenous retrovirus K.

W Vogetseder1, A Dumfahrt, P Mayersbach, D Schönitzer, M P Dierich.   

Abstract

Human endogenous retrovirus (HERV) K is present in about 50 copies in the human genome and transcription of HERV-K has previously been detected in several tumor cell lines as well as in peripheral blood lymphocytes from healthy donors. By means of immunoblotting we investigated the presence of antibodies recognizing recombinant HERV-K-envelope outer membrane constructs in different serum collectives. A total of 12.6% of sera obtained from normal blood donors was found positive. In serum collectives from breast carcinoma patients, HIV-1-positive individuals, and persons with cytomegalovirus infections no significant difference from the normal blood donor serum collective could be observed. Only a group of persons with a repeatedly raised serum neopterin concentration (> 10 nmol/liter) of unknown cause (HIV and hepatitis B and C virus infections were excluded) showed a significant higher percentage of HERV-K-outer membrane envelope-positive sera (21%). Furthermore we could observe a parallel HIV-1/HERV-K seroconversion, which probably is not due to an HIV-1/HERV-K-outer membrane envelope cross-reactivity. Possible implications of these findings are discussed.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8396402     DOI: 10.1089/aid.1993.9.687

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  23 in total

1.  Expression of human endogenous retrovirus K elements in germ cell and trophoblastic tumors.

Authors:  H Herbst; M Sauter; N Mueller-Lantzsch
Journal:  Am J Pathol       Date:  1996-11       Impact factor: 4.307

2.  Retrovirus-like particles released from the human breast cancer cell line T47-D display type B- and C-related endogenous retroviral sequences.

Authors:  W Seifarth; H Skladny; F Krieg-Schneider; A Reichert; R Hehlmann; C Leib-Mösch
Journal:  J Virol       Date:  1995-10       Impact factor: 5.103

Review 3.  Human endogenous retrovirus-K (HML-2): a comprehensive review.

Authors:  Marta Garcia-Montojo; Tara Doucet-O'Hare; Lisa Henderson; Avindra Nath
Journal:  Crit Rev Microbiol       Date:  2018-10-14       Impact factor: 7.624

4.  Physical mapping of sequences homologous to an endogenous retrovirus LTR on human chromosome 19.

Authors:  Y B Lebedev; S V Volik; D Obradovic; O D Ermolaeva; L K Ashworth; G G Lennon; E D Sverdlov
Journal:  Mol Gen Genet       Date:  1995-06-25

5.  The promoter activity of long terminal repeats of the HERV-H family of human retrovirus-like elements is critically dependent on Sp1 family proteins interacting with a GC/GT box located immediately 3' to the TATA box.

Authors:  E Sjøttem; S Anderssen; T Johansen
Journal:  J Virol       Date:  1996-01       Impact factor: 5.103

6.  Identification of three human sequences with viral superantigen-specific primers.

Authors:  S Indraccolo; W H Günzburg; C Leib-Mösch; V Erfle; B Salmons
Journal:  Mamm Genome       Date:  1995-05       Impact factor: 2.957

7.  Endogenous retroviruses in the human genome--a point of view.

Authors:  Y Becker
Journal:  Virus Genes       Date:  1995-02       Impact factor: 2.332

Review 8.  The viruses in all of us: characteristics and biological significance of human endogenous retrovirus sequences.

Authors:  R Löwer; J Löwer; R Kurth
Journal:  Proc Natl Acad Sci U S A       Date:  1996-05-28       Impact factor: 11.205

Review 9.  Evolution and biological significance of human retroelements.

Authors:  C Leib-Mösch; W Seifarth
Journal:  Virus Genes       Date:  1995       Impact factor: 2.332

10.  The IDDM-associated solitary retroviral promoters DQ-LTR3 and DQ-LTR13 have a distinct impact on the expression of selected DQB1 genes in different cell lines in vitro.

Authors:  Katrin Krach; Klaus Badenhoop; Ralf R Tönjes
Journal:  Immunogenetics       Date:  2003-10-18       Impact factor: 2.846

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.